ストックスクリーナーアプリを入手
82.02
3.64%
2.88
アフターアワーズ：
82.02
前日終値:
$79.14
開ける：
$80.12
24時間の取引高:
216.52K
Relative Volume:
0.80
時価総額：
$970.83M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+7.31%
1か月 パフォーマンス:
-18.38%
6か月 パフォーマンス:
+89.82%
1年 パフォーマンス:
+385.90%
1日の値動き範囲:
$78.97
$84.69
1週間の範囲:
$76.50
$85.05
52週間の値動き範囲:
$16.65
$114.69
Palvella Therapeutics Inc Stock (PVLA) Company Profile
名前
Palvella Therapeutics Inc
セクター
電話
(484) 253-1461
住所
353 W. LANCASTER AVENUE, WAYNE
Compare PVLA vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
82.02 | 936.74M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-07 | 開始されました | Mizuho | Outperform |
| 2025-12-05 | 開始されました | BTIG Research | Buy |
| 2025-12-04 | 開始されました | Craig Hallum | Buy |
| 2025-11-19 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2025-09-09 | 開始されました | Oppenheimer | Outperform |
| 2025-08-06 | 開始されました | Raymond James | Outperform |
| 2025-07-21 | 開始されました | Truist | Buy |
| 2025-04-09 | 開始されました | Chardan Capital Markets | Buy |
| 2025-03-26 | 開始されました | Stifel | Buy |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2025-02-20 | 開始されました | Canaccord Genuity | Buy |
| 2025-02-05 | 開始されました | TD Cowen | Buy |
| 2024-12-26 | 開始されました | H.C. Wainwright | Buy |
| 2024-12-18 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-03-13 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2019-07-30 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2019-05-14 | 開始されました | Robert W. Baird | Outperform |
| 2018-03-19 | 開始されました | Evercore ISI | Outperform |
| 2018-03-19 | 開始されました | Jefferies | Buy |
| 2018-01-16 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-05-30 | 開始されました | Rodman & Renshaw | Buy |
| 2016-08-05 | 再開されました | ROTH Capital | Buy |
| 2015-08-12 | 開始されました | JMP Securities | Mkt Outperform |
| 2015-07-27 | 開始されました | Oppenheimer | Outperform |
| 2015-07-22 | 開始されました | ROTH Capital | Buy |
すべてを表示
Palvella Therapeutics Inc (PVLA) 最新ニュース
FY2030 Earnings Forecast for PVLA Issued By HC Wainwright - Defense World
FY2030 Earnings Estimate for PVLA Issued By HC Wainwright - MarketBeat
Notable Friday Option Activity: PVLA, XOM, RUM - Nasdaq
Palvella Therapeutics stock maintains Buy rating at Clear Street ahead of trial data - Investing.com Canada
Palvella Therapeutics (PVLA) Receives a Buy from H.C. Wainwright - The Globe and Mail
LGND: New Year Program Updates - Zacks Small Cap Research
Analysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), HOYA (HOCPF) - The Globe and Mail
Palvella Therapeutics, Inc. Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Por - marketscreener.com
Palvella stock rises after systematic review supports clinical potential By Investing.com - Investing.com Nigeria
Palvella stock rises after systematic review supports clinical potential - Investing.com
Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porok... - Sahm
Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Poroker - ChartMill
TD Cowen raises Palvella Therapeutics stock price target on BTD prospects - Investing.com Canada
Death Cross: Is CYCU in a bullish channelLayoff News & Technical Confirmation Trade Alerts - baoquankhu1.vn
Federated Hermes Inc. Takes $21.26 Million Position in Palvella Therapeutics, Inc. $PVLA - MarketBeat
Palvella Therapeutics, Inc Advances Late-Stage Pipeline - TradingView
Palvella Therapeutics' (PVLA) Buy Rating Reaffirmed at BTIG Research - MarketBeat
What are the risks of holding Dakota Gold Corp. Equity WarrantJuly 2025 Trends & Verified Short-Term Trading Plans - baoquankhu1.vn
Kathleen Goin Sells 4,302 Shares of Palvella Therapeutics (NASDAQ:PVLA) Stock - MarketBeat
Palvella Therapeutics (NASDAQ:PVLA) Stock Price Down 7.8%Here's Why - MarketBeat
Palvella Therapeutics (NASDAQ:PVLA) Pursues Targeted Immune Innovation - Kalkine Media
Published on: 2026-01-23 00:45:18 - baoquankhu1.vn
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
FOMO Trade: Does RAIN stock benefit from AI growthQuarterly Profit Report & Short-Term High Return Ideas - baoquankhu1.vn
Palvella’s QTORIN pipeline targets a breakout moment in rare skin care - MSN
Analyst Calls: Is Palvella Therapeutics Inc stock forming a cup and handle2025 Technical Patterns & Weekly Top Gainers Alerts - baoquankhu1.vn
Analysts Are Bullish on These Healthcare Stocks: Palvella Therapeutics (PVLA), Nurix Therapeutics (NRIX) - The Globe and Mail
Palvella Therapeutics (NASDAQ:PVLA) Earns Buy Rating from BTIG Research - MarketBeat
Palvella taps veteran dermatology executive to steer medical affairs push - MSN
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Short Interest Up 60.9% in December - MarketBeat
Palvella’s rare-disease pipeline gains momentum amid positive topline data - S&P Global
Pharma News: Is Palvella Therapeutics Inc a turnaround storyWeekly Investment Summary & Technical Buy Zone Confirmation - baoquankhu1.vn
Moving Averages: Will Palvella Therapeutics Inc stock reach all time highs in 2025 - Bộ Nội Vụ
Aug Action: Will Palvella Therapeutics Inc stock reach all time highs in 2025 - Bộ Nội Vụ
Aspiriant LLC Acquires Shares of 5,852 Palvella Therapeutics, Inc. $PVLA - Defense World
Palvella Highlights QTORIN Pipeline and 2026 Growth Outlook - TipRanks
Palvella Therapeutics, Inc. Advances Rare Disease Therapies - TradingView — Track All Markets
Assessing Palvella Therapeutics (PVLA) Valuation After Strong One Year Returns And Conflicting Signals - Yahoo Finance
Palvella’s QTORIN Pipeline Targets a Breakout Moment in Rare Skin Care - MyChesCo
Palvella Therapeutics Joins Russell 3000 and Russell 2000 Indexes - MSN
Palvella Therapeutics provides corporate update and 2026 outlook - marketscreener.com
Palvella Therapeutics Provides Corporate Update And 2026 Outlook - TradingView — Track All Markets
Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies - The Manila Times
Palvella Taps Veteran Dermatology Executive to Steer Medical Affairs Push - MyChesCo
Will Palvella Therapeutics Inc. (PI6) stock benefit from commodity supercycleForecast Cut & Proven Capital Preservation Methods - Улправда
A new gel that could become the first treatment for rare skin diseases - Stock Titan
Will Palvella Therapeutics Inc. stock maintain growth storyMarket Growth Summary & Low Drawdown Investment Ideas - Улправда
Palvella Therapeutics stock maintains Buy rating at TD Cowen ahead of key trial data - Investing.com Canada
Why analysts recommend Palvella Therapeutics Inc. (PI6) stockJuly 2025 Big Picture & Advanced Swing Trade Entry Alerts - Улправда
What is the fair value of Palvella Therapeutics Inc. stock now2025 Support & Resistance & Verified Technical Trade Signals - ulpravda.ru
Will Palvella Therapeutics Inc. stock pay special dividendsPortfolio Return Report & Low Risk High Reward Ideas - Улправда
Palvella Therapeutics Inc (PVLA) 財務データ
Palvella Therapeutics Inc (PVLA) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):